initi outperform pt
use stefano amazon
valuat compel w/ perfect candid mean revers
bullish share given belief
relat upsid us pharmaci share gain would yield ep upsid
aid price-to-earnings stabil despit premium peer say wrong
would understat intern busi suffer
fx reimburs took much longer expect
relat fear hit multipl enter hous call
factor rotat valu posit bia toward retail high
yield essenti mean revers play relat risk see
perfectli lever theme contend share see
relief multipl side along exist call option
upsid tax reform
importantli channel check varieti industri expert
suggest market massiv mischaracter amzn intent
pharmaci space acknowledg lt risk on-line
competit abat particularli fe believ market
becom increasingli awar notabl challeng face
also contend transact far ideal final
structur leav wba balanc sheet healthi like allow
capit alloc aggress recent manag
buyer stock see shift back
potenti creativ vertic transact distinct
possibl given dynam see risk reward favor
thu initi share o/p rate
thing watch relat headlin tone vertic
debat role play vertic integr
deal worth time effort wba front
valuat price target base dcf methodolog
contempl wacc termin ebitda multipl
equat perpetu growth rate pt
translat ebitda vs average price-to-earnings basi
translat vs average
downsid risk potenti on-line competit amazon
erod front end comp margin us pharmaci share
continu reimburs pressur us eu hit
ultim lead total margin compress transact prove
challeng increas volum revenu store appear futil
lead poor return posit independ retail us
becom disadvantag vertic integr peer capabl
take notabl share manag unabl locat creativ
transact leav balanc sheet underutil limit total
oper growth beauti push ultim becom distract
momentum build manag must revisit costli rebuild
store format
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect
object report investor consid report singl factor make invest decis
initi outperform pt
use stefano amazon
last page report import disclosur regard stock report
tabl content
debat role play vertic integr
debat deal worth time effort
debat wba front end chang
point differenti vs st
iv valuat risk mean revers vs
 conclus initi outperform greed defeat fear
hybrid pharmacy-distributor global ambit
top perform rx suppli chain basi
global retail pharmaci leader distribut
presenc eu us own
store countri
thesi retail mean revers re-rat multipl
fear abat continu cost manag
rate valuat pt outperform pt
ebitda vs average
price-to-earnings vs average
soft erod om profil free cash flow
stefano team long histori valu creation
previous serv execut chairman
previous serv evp walgreen boot
presid chief execut global
wholesal intern retail
georg fairweath evp global cfo
previous serv group financ director
previous evp
presid walgreen
debat role play vertic integr
new think vertic integr
could vertic integr
sinc origin walgreens-alli boot
transact investor listen close
wba thought structur rx suppli chain
go forward vision lead
commun healthcar provid partner
patient payersw want offer full
rang integr servic solut improv
patient outcom help lower overal cost
vertic integr happen
stagepeopl look save money
part healthcar system use pharmaci
pharmacist pharmaci network effect
reason like given improv patient data
focu medic drug util
improv outcom cost
less like given wba partnership prime
prime partnership allow pbm-
retail option attract financi profil
possibl unlik larg impact
activ acquir global asset
 fasa guoda name recent deal
howev asset stake
take quit small less impact
done alreadi own larg european
distributor allianc stake
given alreadi extract synergi
via wbad unclear complet
ownership would bring
other
potenti intrigu current run
histori support continu integr push creativ bia notabl structur
debat deal worth time effort
deal never endsit went friendsand frustrat manag
ftc
clock
approv
sale
varieti
retail said
interest
said
interest
revis
share
fred
sell
sale
gener msd run-rat accret
obvious smaller origin transact
second one approv deal still provid
return quit appeal
mm integr synergi
mm footprint optim closur
contribut
contribut
rate accret msd attract
turn reason tuck vs anyth transform
debat wba front end chang
dollar store impact wba fe sale
howev longer term on-line sale eat away fe
food drink
fe focu beauty/health boost margin mix
also experi w/more hc servic
although manag releas specif
profit data front end anecdot
note trend line gener posit
front end gross profit margin market share
replac mani gener merchandis
categori well sushi msd gross
margin addit beauti health/wel
product gross margin
chang could help make gross profit dollar
resili store sale number would suggest
like continu devot floor space
healthcar servic well see box right
fe comp like remain soft gp could ultim prove stabl fear
model summari point differenti vs street
swing factor us fe comp slope total om trajectori pace capit alloc
point
w/rad roll fx
modestli street
year
synergi ramp
ep in-lin w/ st
leverag profil
sizeabl
 remain crucial financi model cost effici offset gm pressur
million except per share data fy end august usa pharmaci usa fe total cc sale total cc sale growth revenu margin growth revenu ep share net incom price-to-earnings premium/discount januari
valuat sever impact amazon relat fear
rel valuat went premium execut signific discount competit fear
risk point favor risk reward profil relat fear like peak mean revers like
potenti on-line competit amazon erod front end comp margin us pharmaci share
continu reimburs pressur us eu hit ultim lead total margin compress
transact prove challeng increas volum revenu store appear futil lead poor return
posit independ retail us becom disadvantag vertic integr peer capabl take notabl share
manag unabl locat creativ transact leav balanc sheet underutil limit total oper growth
beauti push ultim becom distract momentum build manag must revisit costli rebuild store format
dcf valuat yield price
dcf deriv pt impli termin growth rate impli ebitda multipl
assumpt underli dcf valuat methodolog
year ebita margin assumpt
termin ebitda multipl
wacc base beta risk free rate cost debt
tax rate
assumpt impli termin growth rate
discount ebitda termin free flow enterpris total valu valu per perpetu growth valu enterpris enterpris valu januari
conclus initi outperform pt upsid
forese investor return given yield likeli fear abat
bullish share given belief relat upsid us
pharmaci share gain would yield ep upsid aid price-to-earnings stabil despit premium peer
say wrong would understat intern busi suffer fx
 reimburs took much longer expect relat fear hit multipl
enter hous call factor rotat valu posit bia toward
retail high yield essenti mean revers play relat risk
see perfectli leverag theme contend share see relief
multipl side along exist call option upsid tax reform
importantli channel check varieti industri expert suggest market
massiv mischaracter amzn intent pharmaci space
acknowledg lt risk on-line competit abat particularli fe
believ market becom increasingli awar notabl challeng face
also contend transact far ideal final structur leav
wba balanc sheet healthi like allow capit alloc aggress
recent manag buyer stock see shift back
 potenti creativ vertic transact distinct possibl
given dynam see risk reward favor thu initi share o/p rate
thing watch relat headlin tone vertic integr om trajectori
pleas feel free reach question follow-up
medic suppli devic
valuat price target base dcf methodolog contempl wacc termin ebitda
multipl equat perpetu growth rate pt translat ebitda vs average
price-to-earnings basi translat vs average
downsid risk potenti on-line competit amazon erod front end comp margin us
pharmaci share continu reimburs pressur us eu hit ultim lead total margin compress
transact prove challeng increas volum revenu store appear futil lead poor return posit
independ retail us becom disadvantag vertic integr peer capabl take notabl share manag
unabl locat creativ transact leav balanc sheet underutil limit total oper growth beauti push
ultim becom distract momentum build manag must revisit costli rebuild store format
articl articl
time dissemin januari et
analyst ross muken elizabeth anderson suzi yoon primarili respons prepar research report attest
follow view opinion render research report reflect person view subject compani issuer
part research analyst compens directli relat specif recommend view
